Please assess the completion status of the following clinical trial:

Trial Title: Asthma Exacerbation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of asthma~* Reversibility FEV1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol~* FEV1 of fifty to ninety percent of predicted~* Currently using inhaled corticosteroid therapy~* History of one or more asthma exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization in previous year~Exclusion Criteria:~* History of life threatening asthma in previous 5 years (requiring intubation, and/or associated with hypercapnia, hypoxic seizure or respiratory arrest~* Respiratory infection or oral candidiasis~* - Uncontrolled disease or clinical abnormality~* Allergies~* Taking another investigational medication or prohibited medication

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate/GW642444 (Type: EXPERIMENTAL): None
- fluticasone furoate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).